Inventor · disambiguated record
Nikolai Kley
Also filed as: KLEY NIKOLAI · KLEY NIKOLAI A
30 granted patents·28 pending applications·263 citations·filing 1994–2025
96Inventor score
Files withORIONIS BIOSCIENCES INC33Orionis Biosciences BV16BRISTOL MYERS SQUIBB CO5GPC BIOTECH AG1GPC BIOTECH INC1
Top patents by PatentIndex Score
58 records- 0195US7135550B2Three hybrid assay systemGPC BIOTECH AG·Filed 2002·Granted Nov 14, 2006·126 cites·37 claims
- 0294US11236166B2CD8 binding agentsOrionis Biosciences BV·Filed 2017·Granted Feb 1, 2022·10 cites·9 claims
- 0394US11001631B2Clec9A binding agentsOrionis Biosciences BV·Filed 2017·Granted May 11, 2021·12 cites·17 claims
- 0493US10906985B2Targeted engineered interferon and uses thereofORIONIS BIOSCIENCES INC·Filed 2018·Granted Feb 2, 2021·8 cites·16 claims
- 0592US11236141B2Targeted mutant interferon-beta and uses thereofOrionis Biosciences BV·Filed 2017·Granted Feb 1, 2022·7 cites·16 claims
- 0691US10988538B2Bispecific signaling agents and uses thereofOrionis Biosciences BV·Filed 2017·Granted Apr 27, 2021·9 cites·45 claims
- 0790US11440943B2Therapeutic interferon alpha 1 proteinsORIONIS BIOSCIENCES INC·Filed 2020·Granted Sep 13, 2022·2 cites·11 claims
- 0888US11661455B2Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moietyOrionis Biosciences BV·Filed 2017·Granted May 30, 2023·4 cites·6 claims
- 0987US12473338B2Targeted engineered interferon and uses thereofORIONIS BIOSCIENCES INC·Filed 2020·Granted Nov 18, 2025·1 cites·6 claims
- 1087US11084859B2Targeted mutant interferon-gamma and uses thereofORIONIS BIOSCIENCES NV·Filed 2017·Granted Aug 10, 2021·6 cites·29 claims
- 1186US11384154B2Targeted chimeric proteins and uses thereofOrionis Biosciences BV·Filed 2018·Granted Jul 12, 2022·5 cites·12 claims
- 1281US2025066486A1Clec9a binding agents and use thereofORIONIS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 1380US12091463B2Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH)ORIONIS BIOSCIENCES INC·Filed 2018·Granted Sep 17, 2024·1 cites·8 claims
- 1480US2024360224A1Clec9a binding agents and use thereofORIONIS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 1579US12364753B2CD8 binding agentsOrionis Biosciences BV·Filed 2021·Granted Jul 22, 2025·0 cites·16 claims
- 1679US12084497B2SIRP1α targeted chimeric proteins and uses thereofORIONIS BIOSCIENCES INC·Filed 2019·Granted Sep 10, 2024·1 cites·14 claims
- 1779US11753463B2Therapeutic targeting of non-cellular structuresOrionis Biosciences BV·Filed 2017·Granted Sep 12, 2023·2 cites·13 claims
- 1879US11498966B2PD-1 and PD-L1 binding agentsORIONIS BIOSCIENCES INC·Filed 2018·Granted Nov 15, 2022·1 cites·8 claims
- 1978US11566072B2CD8 binding agentsORIONIS BIOSCIENCES INC·Filed 2018·Granted Jan 31, 2023·1 cites·22 claims
- 2078US2025361305A1Pd-1 and pd-l1 binding agentsORIONIS BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 2176US12453770B2CLEC9A binding agentsOrionis Biosciences BV·Filed 2021·Granted Oct 28, 2025·0 cites·11 claims
- 2276US12351633B2PD-1 and PD-L1 binding agentsORIONIS BIOSCIENCES INC·Filed 2022·Granted Jul 8, 2025·0 cites·16 claims
- 2376US11896643B2Fibroblast binding agents and use thereofORIONIS BIOSCIENCES INC·Filed 2019·Granted Feb 13, 2024·1 cites·11 claims
- 2476US5840673AInsulin-like growth factor binding protein 3 (IGF-BP3) in treatment of p53-related tumorsBRISTOL MYERS SQUIBB CO·Filed 1996·Granted Nov 24, 1998·43 cites·4 claims
- 2575US2024368277A1SIRP1a TARGETED CHIMERIC PROTEINS AND USES THEREOFORIONIS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 2673US12497436B2Chimeric protein, and encoding nucleic acid thereof, comprising interferon-β and a targeting moiety comprising a single-domain antibody or single-chain antibodyOrionis Biosciences BV·Filed 2021·Granted Dec 16, 2025·0 cites·9 claims
- 2772US12448447B2CD8 binding agentsORIONIS BIOSCIENCES INC·Filed 2022·Granted Oct 21, 2025·0 cites·14 claims
- 2872US2023399406A1Targeted therapeutic agents and uses thereofOrionis Biosciences BV·Filed 2023·Application pending·0 cites
- 2970US2021139586A1Bispecific signaling agents and uses thereofOrionis Biosciences BV·Filed 2020·Application pending·0 cites
- 3069US2024025980A1Therapeutic targeting of non-cellular structuresOrionis Biosciences BV·Filed 2023·Application pending·0 cites
- 3168US2025353890A1Clec9a-based chimeric protein complexesORIONIS BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 3268US2022281992A1Targeted chimeric proteins and uses thereofOrionis Biosciences BV·Filed 2022·Application pending·0 cites
- 3365US12351614B2CLEC9A-based chimeric protein complexesORIONIS BIOSCIENCES INC·Filed 2020·Granted Jul 8, 2025·0 cites·5 claims
- 3465US2023287131A1Bi-functional chimeric proteins and uses thereofOrionis Biosciences BV·Filed 2023·Application pending·0 cites
- 3562US2024400633A1Split human ifn-gamma and tnf-alpha constructs and uses thereofORIONIS BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3661US2024358826A1Interleukin-1 alpha chimeric proteinORIONIS BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3761US2025171531A1Il-2 trap moleculesORIONIS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3858US2024199714A1Il-2 based constructsORIONIS BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3956US2023293652A1Immunostimulatory adjuvantsORIONIS BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 4054US5886149AP53 response genesBRISTOL MYERS SQUIBB CO·Filed 1996·Granted Mar 23, 1999·7 cites·3 claims
- 4153US2023002493A1Pd-l1 targeted chimeric proteins and uses thereofORIONIS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4253US2022378925A1Conjugated chimeric proteinsORIONIS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4352US12410225B2Modulation of dendritic cell lineagesORIONIS BIOSCIENCES INC·Filed 2019·Granted Sep 9, 2025·0 cites·17 claims
- 4451US2023116707A1Detection of novel degradation-related interactionsORIONIS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4551US2022177550A1Chimeric proteins and chimeric protein complexes directed to fms-like tyrosine kinase 3 (flt3)ORIONIS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4651US2022185857A1Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteinsORIONIS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4749US11702477B2Bi-functional chimeric proteins and uses thereofOrionis Biosciences BV·Filed 2016·Granted Jul 18, 2023·0 cites·10 claims
- 4849US2023026360A1Detection of molecular interactionsORIONIS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4947US2021024631A1Bi-functional proteins and construction thereofORIONIS BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 5047US2020354424A1Xcr1 binding agents and uses thereofORIONIS BIOSCIENCES INC·Filed 2019·Application pending·0 cites
Showing the top 50 of 58 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Nikolai Kley files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →